Breadcrumb

CHAL  |  Cardiovascular Health across the Lifespan Program

Our Researchers

The Cardiovascular Health Across the Lifespan (CHAL) Program brings together seven basic researchers, thirty clinician-scientists and eight health outcomes researchers. Researchers from the Centre for Translational Biology (CTB) conduct basic research projects related to vascular function and related diseases, especially atherosclerosis, hypercholesterolemia and vascular injury. Investigators from the Centre for Innovative Medicine (CIM) focus their research on surgery outcomes and on improving prevention and care in patients affected by such cardiac diseases as heart failure, arrhythmias and valve diseases. Investigators from the Centre for Outcomes Research and Evaluation (CORE) seek to develop networks, databases and new tools to improve population health. These include epidemiological outcome and intervention studies on congenital heart disease (CHD), and different factors (genetic, environmental, gender-based) for cardiovascular diseases. CHAL researchers are based at the Glen site, at the heritage site of the Royal Victoria Hospital of the MUHC and at 5252 de Maisonneuve Boulevard W.

Filters icon icon

Displaying 7 result(s).

Renzo Cecere, MD

Heart failure

heart assist devices

mitral valve

stem cells

medical device design

CTB

Stella Daskalopoulou, MD, M.Sc., DIC, PhD

atherosclerosis

vascular biology

arterial stiffness and vessel hemodynamics

hypertension

cardiovascular risk factors

CTB

James Engert, PhD

genetic association studies

single-nucleotide polymorphisms (SNPs)

gene-environment interactions

atherosclerosis

aortic stenosis

CTB

Jacques Genest, MD, FRCP(C)

lipoproteins

high-density lipoprotein (HDL)

familial hypercholesterolemia

genetics

ABCA1

CTB

Robert Kiss, PhD

cholesterol

intracellular trafficking

cell biology

microscopy

CTB

Adel Schwertani, PhD

Cardiology

heart

vasoactive substances

atherosclerosis

pulmonary hypertension

CTB

Explore what the CHAL Program has to offer